Lv7
4930 积分 2021-09-21 加入
Bidirectional crosstalk of the gut–liver axis in metabolic dysfunction-associated steatotic liver disease
16天前
已完结
Dual roles of T cells in metabolic dysfunction–associated steatohepatitis pathogenesis and liver fibrosis: From inflammation to therapeutic targets
16天前
已完结
B cells in metabolic dysfunction-associated steatotic liver disease (MASLD): From mechanisms to therapeutic exploration
16天前
已完结
Nuclear Factor I‐B Delays Liver Fibrosis by Inhibiting Chemokine Ligand 5 Transcription
16天前
已完结
Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease
18天前
已完结
Spatially resolved multi-omics of human metabolic dysfunction-associated steatotic liver disease
18天前
已完结
Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management
18天前
已完结
Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities
18天前
已完结
Toward a CKLM framework for integrated clinical trial design
18天前
已完结
Heart–liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework
18天前
已完结
皖公网安备34019202002308
